


Treatment period
Vehicle Control; p.o. bid x 21
MLN8237; p.o. 20 mg/kg qd x 21
Taxol; 15mg/kg i.v. once weekly x3
MLN8237; p.o. 20 mg/kg qd x 21+ Taxol, 15mg/kg i.v. once weekly x3
Topotecan; 1.5mg/kg i.v. qd x5
Average Tumor Volume (mm^3)
1800.0
1600.0
1400.0
1200.0
1000.0
800.0
600.0
400.0
200.0
0.0
0
10
20
30
40
50
60
Days

FIG. 1


Treatment period
CONTROL, PO, QDx21
MLN8237, 20mg/kg, PO, BIDx21
MLN8237, 20mg/kg, PO, QDx21
Paclitaxel, 30 mg/kg, IV, Q7Dx3
MLN8237, 20mg/kg, PO, QDx21 + Paclitaxel, 30mg/kg, IV, Q7Dx3
Average Tumor Volume (mm^3)
Days Post treatment
0
500
1000
1500
2000
2500
3000
0
10
20
30
40



Treatment period
CONTROL, PO, QDx21
MLN8237, 10mg/kg, PO, QDx21
Paclitaxel,15mg/kg, IV, Q7Dx3
MLN8237, 10mg/kg, PO, QDx21 + Paclitaxel, 15mg/kg, IV, Q7Dx3
Average Tumor Volume (mm^3)
Days Post Treatment
0
500
1000
1500
2000
2500
3000
0
10
20
30
40

FIG. 2



Average Tumor Volume (mm^3)
1800.0
1600.0
1400.0
1200.0
1000.0
800.0
600.0
400.0
200.0
0.0
0
10
20
30
40
50
60
Days
Treatment period
Vehicle Control; p.o. bid x 21
MLN8237; p.o. 20 mg/kg qd x 21
Taxol; 15mg/kg i.v. once weekly x3
MLN8237; p.o. 20 mg/kg qd x 21+ Taxol, 15mg/kg i.v. once weekly x3
Topotecan; 1.5mg/kg i.v. qd x5

FIG. 3